Reversal of iron-induced dilated cardiomyopathy during therapy with deferasirox in beta-thalassemia.
A 15-year-old male with beta-thalassemia major developed dilated cardiomyopathy secondary to iron-overload (Z-scores of left ventricle (LV) dimensions >3, ejection fraction (EF) 33%). Treatment with deferoxamine was unsuccessful, presumably due to poor compliance. After 15 months of using deferasirox (DFX), LV end-diastolic dimension normalized (Z-scores <2), and EF improved to 58%. We conclude that treatment with DFX resulted in a reversal of iron-induced cardiomyopathy.
Trad
Omar
O
Department of Pediatrics, Division of Hematology, Tawam Hospital-in-Affiliation with Johns Hopkins Medicine, Al Ain, United Arab Emirates. oatrad@hotmail.com
Hamdan
Mohamed A
MA
Jamil
Altaf
A
Khanani
Muhammad F
MF
Ishaqi
M Kashif
MK
Shamsi
Aisha
A
Hayek
Mohamed
M
D000293:Adolescent; D001565:Benzoates / Q000627:therapeutic use*; D002311:Cardiomyopathy, Dilated / Q000097:blood* / Q000150:complications*; D000077588:Deferasirox; D006801:Humans; D007501:Iron / Q000097:blood*; D008297:Male; D014230:Triazoles / Q000627:therapeutic use*; D017086:beta-Thalassemia / Q000097:blood* / Q000150:complications / Q000188:drug therapy*
D001565:Benzoates; D014230:Triazoles; D007501:Iron; D000077588:Deferasirox